TY - GEN
T1 - Cancer Imaging with Nanoparticles Using MARS Spectral Scanner
AU - Moghiseh, Mahdieh
AU - Raja, Aamir
AU - Kumar, Dhiraj
AU - Panta, Raj
AU - Healy, Joseph L.
N1 - Funding Information:
Manuscript received December 14, 2018. This project was funded by the Ministry of Business, Innovation and Employment (MBIE), New Zealand under contract number UOCX1404, by MARS Bioimaging Ltd and the Ministry of Education through the MedTech CoRE. The authors would like to acknowledge the Medipix2, Medipix3 and Medipix4 collaboration.
Publisher Copyright:
© 2018 IEEE.
PY - 2018/11
Y1 - 2018/11
N2 - Treatment failure in cancer is often due to variation in tumour characteristics within the same tumour, or across tumour sites, or over time. At present, most cancers are staged with imaging; treatment is selected, then the patient is re-imaged to see if the treatment is working. We intend to transform that approach by using a novel non-invasive spectral imaging technology together with targeted and non-targeted gold nanoparticles to measure tumour burden as well as drug delivery. In this study, we report spectral CT imaging of four different cancer cell types (ovarian, breast, Raji cancer cells and Lewis lung carcinoma) using gold nanoparticles. We also report that drug labelled targeted gold nanoparticles can specifically target HER2+ breast cancer cells and can be quantified by a spectral scanner. MARS CT incorporated with Medipix3RX detector was used. For image acquisition, four energy thresholds were set between 18 to 118keV to detect the K-edge of gold nanoparticles. Reconstructed images in narrow energy bins were used for material decomposition. In the first study, two ovarian cancer cell lines (OVCAR5 and SKOV3) were incubated in four sizes of gold nanoparticles (18, 40, 60 and 80nm). Results indicated a high uptake of 18 and 80nm of the gold nanoparticle by SKOV3; OVCAR5 show less uptake for all four nanoparticle sizes. In the second study, Lewis lung carcinoma was implanted in C57BL mice, and 15nm non-functionalized gold nanoparticles were injected via tail vein. Gold nanoparticles were visualized and quantified (0.497mg) in the peripheral region of a tumour whilst showing tumour necrosis in the middle. The third study showed the successful cross-over experiment of gold nanoparticles labelled to two drugs, Rituximab, and Herceptin to target Raji, and breast cancer cells respectively. The findings demonstrated spectral CT has the potential to enable the imaging and quantification of nanoparticles to monitor biological or disease processes and drug delivery to specific cell types.
AB - Treatment failure in cancer is often due to variation in tumour characteristics within the same tumour, or across tumour sites, or over time. At present, most cancers are staged with imaging; treatment is selected, then the patient is re-imaged to see if the treatment is working. We intend to transform that approach by using a novel non-invasive spectral imaging technology together with targeted and non-targeted gold nanoparticles to measure tumour burden as well as drug delivery. In this study, we report spectral CT imaging of four different cancer cell types (ovarian, breast, Raji cancer cells and Lewis lung carcinoma) using gold nanoparticles. We also report that drug labelled targeted gold nanoparticles can specifically target HER2+ breast cancer cells and can be quantified by a spectral scanner. MARS CT incorporated with Medipix3RX detector was used. For image acquisition, four energy thresholds were set between 18 to 118keV to detect the K-edge of gold nanoparticles. Reconstructed images in narrow energy bins were used for material decomposition. In the first study, two ovarian cancer cell lines (OVCAR5 and SKOV3) were incubated in four sizes of gold nanoparticles (18, 40, 60 and 80nm). Results indicated a high uptake of 18 and 80nm of the gold nanoparticle by SKOV3; OVCAR5 show less uptake for all four nanoparticle sizes. In the second study, Lewis lung carcinoma was implanted in C57BL mice, and 15nm non-functionalized gold nanoparticles were injected via tail vein. Gold nanoparticles were visualized and quantified (0.497mg) in the peripheral region of a tumour whilst showing tumour necrosis in the middle. The third study showed the successful cross-over experiment of gold nanoparticles labelled to two drugs, Rituximab, and Herceptin to target Raji, and breast cancer cells respectively. The findings demonstrated spectral CT has the potential to enable the imaging and quantification of nanoparticles to monitor biological or disease processes and drug delivery to specific cell types.
UR - http://www.scopus.com/inward/record.url?scp=85073108126&partnerID=8YFLogxK
U2 - 10.1109/NSSMIC.2018.8824632
DO - 10.1109/NSSMIC.2018.8824632
M3 - Conference contribution
AN - SCOPUS:85073108126
T3 - 2018 IEEE Nuclear Science Symposium and Medical Imaging Conference, NSS/MIC 2018 - Proceedings
BT - 2018 IEEE Nuclear Science Symposium and Medical Imaging Conference, NSS/MIC 2018 - Proceedings
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 2018 IEEE Nuclear Science Symposium and Medical Imaging Conference, NSS/MIC 2018
Y2 - 10 November 2018 through 17 November 2018
ER -
